← 產業報告目錄
Bioengineered Protein Drugs Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 121報告編號 APO-1d840f302f
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Bioengineered Protein Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Bioengineered Protein Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Bioengineered Protein Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Bioengineered Protein Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Bioengineered Protein Drugs include Amoytop Biotech, Dr.Reddy’s, Fresenius, Hualan Bio, Panacea Biotech, ProBioGen, Reliance Life Sciences, Shanghai United Cell Biotechnology and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Bioengineered Protein Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bioengineered Protein Drugs Market by Company
Amoytop Biotech
Dr.Reddy’s
Fresenius
Hualan Bio
Panacea Biotech
ProBioGen
Reliance Life Sciences
Shanghai United Cell Biotechnology
GlaxoSmithKline
Eli Lilly
Roche
Merck
Novartis
Sanofi
Bioengineered Protein Drugs Segment by Type
Therapeutic Proteins
Vaccines
Monoclonal Antibodies
Bioengineered Protein Drugs Segment by Application
Autoimmune Disorder
Diabetes
Neurodegenerative
Infectious Disease
Cancer
Others
Bioengineered Protein Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bioengineered Protein Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bioengineered Protein Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bioengineered Protein Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bioengineered Protein Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bioengineered Protein Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bioengineered Protein Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Bioengineered Protein Drugs Market Size (2021-2032)
2.2.2 Global Bioengineered Protein Drugs Sales (2021-2032)
2.2.3 Global Bioengineered Protein Drugs Market Average Price (2021-2032)
2.3 Bioengineered Protein Drugs by Type
2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
2.3.2 Therapeutic Proteins
2.3.3 Vaccines
2.3.4 Monoclonal Antibodies
2.4 Bioengineered Protein Drugs by Application
2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.4.2 Autoimmune Disorder
2.4.3 Diabetes
2.4.4 Neurodegenerative
2.4.5 Infectious Disease
2.4.6 Cancer
2.4.7 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Bioengineered Protein Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
3.2 Global Bioengineered Protein Drugs Sales (K Units) of Manufacturers (2021-2026)
3.3 Global Bioengineered Protein Drugs Revenue of Manufacturers (2021-2026)
3.4 Global Bioengineered Protein Drugs Average Price by Manufacturers (2021-2026)
3.5 Global Bioengineered Protein Drugs Industry Ranking, 2024 VS 2025 VS 2026
3.6 Global Manufacturers of Bioengineered Protein Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Bioengineered Protein Drugs, Product Type & Application
3.8 Global Manufacturers of Bioengineered Protein Drugs, Established Date
3.9 Global Bioengineered Protein Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Amoytop Biotech
4.1.1 Amoytop Biotech Company Information
4.1.2 Amoytop Biotech Business Overview
4.1.3 Amoytop Biotech Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.1.4 Amoytop Biotech Bioengineered Protein Drugs Product Portfolio
4.1.5 Amoytop Biotech Recent Developments
4.2 Dr.Reddy’s
4.2.1 Dr.Reddy’s Company Information
4.2.2 Dr.Reddy’s Business Overview
4.2.3 Dr.Reddy’s Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.2.4 Dr.Reddy’s Bioengineered Protein Drugs Product Portfolio
4.2.5 Dr.Reddy’s Recent Developments
4.3 Fresenius
4.3.1 Fresenius Company Information
4.3.2 Fresenius Business Overview
4.3.3 Fresenius Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.3.4 Fresenius Bioengineered Protein Drugs Product Portfolio
4.3.5 Fresenius Recent Developments
4.4 Hualan Bio
4.4.1 Hualan Bio Company Information
4.4.2 Hualan Bio Business Overview
4.4.3 Hualan Bio Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.4.4 Hualan Bio Bioengineered Protein Drugs Product Portfolio
4.4.5 Hualan Bio Recent Developments
4.5 Panacea Biotech
4.5.1 Panacea Biotech Company Information
4.5.2 Panacea Biotech Business Overview
4.5.3 Panacea Biotech Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.5.4 Panacea Biotech Bioengineered Protein Drugs Product Portfolio
4.5.5 Panacea Biotech Recent Developments
4.6 ProBioGen
4.6.1 ProBioGen Company Information
4.6.2 ProBioGen Business Overview
4.6.3 ProBioGen Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.6.4 ProBioGen Bioengineered Protein Drugs Product Portfolio
4.6.5 ProBioGen Recent Developments
4.7 Reliance Life Sciences
4.7.1 Reliance Life Sciences Company Information
4.7.2 Reliance Life Sciences Business Overview
4.7.3 Reliance Life Sciences Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.7.4 Reliance Life Sciences Bioengineered Protein Drugs Product Portfolio
4.7.5 Reliance Life Sciences Recent Developments
4.8 Shanghai United Cell Biotechnology
4.8.1 Shanghai United Cell Biotechnology Company Information
4.8.2 Shanghai United Cell Biotechnology Business Overview
4.8.3 Shanghai United Cell Biotechnology Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.8.4 Shanghai United Cell Biotechnology Bioengineered Protein Drugs Product Portfolio
4.8.5 Shanghai United Cell Biotechnology Recent Developments
4.9 GlaxoSmithKline
4.9.1 GlaxoSmithKline Company Information
4.9.2 GlaxoSmithKline Business Overview
4.9.3 GlaxoSmithKline Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.9.4 GlaxoSmithKline Bioengineered Protein Drugs Product Portfolio
4.9.5 GlaxoSmithKline Recent Developments
4.10 Eli Lilly
4.10.1 Eli Lilly Company Information
4.10.2 Eli Lilly Business Overview
4.10.3 Eli Lilly Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.10.4 Eli Lilly Bioengineered Protein Drugs Product Portfolio
4.10.5 Eli Lilly Recent Developments
4.11 Roche
4.11.1 Roche Company Information
4.11.2 Roche Business Overview
4.11.3 Roche Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.11.4 Roche Bioengineered Protein Drugs Product Portfolio
4.11.5 Roche Recent Developments
4.12 Merck
4.12.1 Merck Company Information
4.12.2 Merck Business Overview
4.12.3 Merck Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.12.4 Merck Bioengineered Protein Drugs Product Portfolio
4.12.5 Merck Recent Developments
4.13 Novartis
4.13.1 Novartis Company Information
4.13.2 Novartis Business Overview
4.13.3 Novartis Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.13.4 Novartis Bioengineered Protein Drugs Product Portfolio
4.13.5 Novartis Recent Developments
4.14 Sanofi
4.14.1 Sanofi Company Information
4.14.2 Sanofi Business Overview
4.14.3 Sanofi Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2021-2026)
4.14.4 Sanofi Bioengineered Protein Drugs Product Portfolio
4.14.5 Sanofi Recent Developments
5 Global Bioengineered Protein Drugs Market Scenario by Region
5.1 Global Bioengineered Protein Drugs Market Size by Region: 2021 VS 2025 VS 2032
5.2 Global Bioengineered Protein Drugs Sales by Region: 2021-2032
5.2.1 Global Bioengineered Protein Drugs Sales by Region: 2021-2026
5.2.2 Global Bioengineered Protein Drugs Sales by Region: 2027-2032
5.3 Global Bioengineered Protein Drugs Revenue by Region: 2021-2032
5.3.1 Global Bioengineered Protein Drugs Revenue by Region: 2021-2026
5.3.2 Global Bioengineered Protein Drugs Revenue by Region: 2027-2032
5.4 North America Bioengineered Protein Drugs Market Facts & Figures by Country
5.4.1 North America Bioengineered Protein Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.4.2 North America Bioengineered Protein Drugs Sales by Country (2021-2032)
5.4.3 North America Bioengineered Protein Drugs Revenue by Country (2021-2032)
5.4.4 United States
5.4.5 Canada
5.5 Europe Bioengineered Protein Drugs Market Facts & Figures by Country
5.5.1 Europe Bioengineered Protein Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.5.2 Europe Bioengineered Protein Drugs Sales by Country (2021-2032)
5.5.3 Europe Bioengineered Protein Drugs Revenue by Country (2021-2032)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Bioengineered Protein Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific Bioengineered Protein Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.6.2 Asia Pacific Bioengineered Protein Drugs Sales by Country (2021-2032)
5.6.3 Asia Pacific Bioengineered Protein Drugs Revenue by Country (2021-2032)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Bioengineered Protein Drugs Market Facts & Figures by Country
5.7.1 South America Bioengineered Protein Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.7.2 South America Bioengineered Protein Drugs Sales by Country (2021-2032)
5.7.3 South America Bioengineered Protein Drugs Revenue by Country (2021-2032)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.7.7 Colombia
5.8 Middle East and Africa Bioengineered Protein Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Bioengineered Protein Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa Bioengineered Protein Drugs Sales by Country (2021-2032)
5.8.3 Middle East and Africa Bioengineered Protein Drugs Revenue by Country (2021-2032)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Bioengineered Protein Drugs Sales by Type (2021-2032)
6.1.1 Global Bioengineered Protein Drugs Sales by Type (2021-2032) & (K Units)
6.1.2 Global Bioengineered Protein Drugs Sales Market Share by Type (2021-2032)
6.2 Global Bioengineered Protein Drugs Revenue by Type (2021-2032)
6.2.1 Global Bioengineered Protein Drugs Sales by Type (2021-2032) & (US$ Million)
6.2.2 Global Bioengineered Protein Drugs Revenue Market Share by Type (2021-2032)
6.3 Global Bioengineered Protein Drugs Price by Type (2021-2032)
7 Segment by Application
7.1 Global Bioengineered Protein Drugs Sales by Application (2021-2032)
7.1.1 Global Bioengineered Protein Drugs Sales by Application (2021-2032) & (K Units)
7.1.2 Global Bioengineered Protein Drugs Sales Market Share by Application (2021-2032)
7.2 Global Bioengineered Protein Drugs Revenue by Application (2021-2032)
7.2.1 Global Bioengineered Protein Drugs Sales by Application (2021-2032) & (US$ Million)
7.2.2 Global Bioengineered Protein Drugs Revenue Market Share by Application (2021-2032)
7.3 Global Bioengineered Protein Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Bioengineered Protein Drugs Value Chain Analysis
8.1.1 Bioengineered Protein Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Bioengineered Protein Drugs Production Mode & Process
8.2 Bioengineered Protein Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Bioengineered Protein Drugs Distributors
8.2.3 Bioengineered Protein Drugs Customers
9 Global Bioengineered Protein Drugs Analyzing Market Dynamics
9.1 Bioengineered Protein Drugs Industry Trends
9.2 Bioengineered Protein Drugs Industry Drivers
9.3 Bioengineered Protein Drugs Industry Opportunities and Challenges
9.4 Bioengineered Protein Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Bioengineered Protein Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Bioengineered Protein Drugs Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Bioengineered Protein Drugs Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Bioengineered Protein Drugs Revenue of Manufacturers (2021-2026)
Table 9. Global Bioengineered Protein Drugs Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Bioengineered Protein Drugs Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Bioengineered Protein Drugs Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Bioengineered Protein Drugs, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Bioengineered Protein Drugs, Product Type & Application
Table 14. Global Bioengineered Protein Drugs Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Bioengineered Protein Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Amoytop Biotech Company Information
Table 19. Amoytop Biotech Business Overview
Table 20. Amoytop Biotech Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Amoytop Biotech Bioengineered Protein Drugs Product Portfolio
Table 22. Amoytop Biotech Recent Developments
Table 23. Dr.Reddy’s Company Information
Table 24. Dr.Reddy’s Business Overview
Table 25. Dr.Reddy’s Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Dr.Reddy’s Bioengineered Protein Drugs Product Portfolio
Table 27. Dr.Reddy’s Recent Developments
Table 28. Fresenius Company Information
Table 29. Fresenius Business Overview
Table 30. Fresenius Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Fresenius Bioengineered Protein Drugs Product Portfolio
Table 32. Fresenius Recent Developments
Table 33. Hualan Bio Company Information
Table 34. Hualan Bio Business Overview
Table 35. Hualan Bio Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Hualan Bio Bioengineered Protein Drugs Product Portfolio
Table 37. Hualan Bio Recent Developments
Table 38. Panacea Biotech Company Information
Table 39. Panacea Biotech Business Overview
Table 40. Panacea Biotech Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Panacea Biotech Bioengineered Protein Drugs Product Portfolio
Table 42. Panacea Biotech Recent Developments
Table 43. ProBioGen Company Information
Table 44. ProBioGen Business Overview
Table 45. ProBioGen Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. ProBioGen Bioengineered Protein Drugs Product Portfolio
Table 47. ProBioGen Recent Developments
Table 48. Reliance Life Sciences Company Information
Table 49. Reliance Life Sciences Business Overview
Table 50. Reliance Life Sciences Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Reliance Life Sciences Bioengineered Protein Drugs Product Portfolio
Table 52. Reliance Life Sciences Recent Developments
Table 53. Shanghai United Cell Biotechnology Company Information
Table 54. Shanghai United Cell Biotechnology Business Overview
Table 55. Shanghai United Cell Biotechnology Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Shanghai United Cell Biotechnology Bioengineered Protein Drugs Product Portfolio
Table 57. Shanghai United Cell Biotechnology Recent Developments
Table 58. GlaxoSmithKline Company Information
Table 59. GlaxoSmithKline Business Overview
Table 60. GlaxoSmithKline Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. GlaxoSmithKline Bioengineered Protein Drugs Product Portfolio
Table 62. GlaxoSmithKline Recent Developments
Table 63. Eli Lilly Company Information
Table 64. Eli Lilly Business Overview
Table 65. Eli Lilly Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Eli Lilly Bioengineered Protein Drugs Product Portfolio
Table 67. Eli Lilly Recent Developments
Table 68. Roche Company Information
Table 69. Roche Business Overview
Table 70. Roche Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Roche Bioengineered Protein Drugs Product Portfolio
Table 72. Roche Recent Developments
Table 73. Merck Company Information
Table 74. Merck Business Overview
Table 75. Merck Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Merck Bioengineered Protein Drugs Product Portfolio
Table 77. Merck Recent Developments
Table 78. Novartis Company Information
Table 79. Novartis Business Overview
Table 80. Novartis Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Novartis Bioengineered Protein Drugs Product Portfolio
Table 82. Novartis Recent Developments
Table 83. Sanofi Company Information
Table 84. Sanofi Business Overview
Table 85. Sanofi Bioengineered Protein Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Sanofi Bioengineered Protein Drugs Product Portfolio
Table 87. Sanofi Recent Developments
Table 88. Global Bioengineered Protein Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 89. Global Bioengineered Protein Drugs Sales by Region (2021-2026) & (K Units)
Table 90. Global Bioengineered Protein Drugs Sales Market Share by Region (2021-2026)
Table 91. Global Bioengineered Protein Drugs Sales by Region (2027-2032) & (K Units)
Table 92. Global Bioengineered Protein Drugs Sales Market Share by Region (2027-2032)
Table 93. Global Bioengineered Protein Drugs Revenue by Region (2021-2026) & (US$ Million)
Table 94. Global Bioengineered Protein Drugs Revenue Market Share by Region (2021-2026)
Table 95. Global Bioengineered Protein Drugs Revenue by Region (2027-2032) & (US$ Million)
Table 96. Global Bioengineered Protein Drugs Revenue Market Share by Region (2027-2032)
Table 97. North America Bioengineered Protein Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 98. North America Bioengineered Protein Drugs Sales by Country (2021-2026) & (K Units)
Table 99. North America Bioengineered Protein Drugs Sales by Country (2027-2032) & (K Units)
Table 100. North America Bioengineered Protein Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 101. North America Bioengineered Protein Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 102. Europe Bioengineered Protein Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 103. Europe Bioengineered Protein Drugs Sales by Country (2021-2026) & (K Units)
Table 104. Europe Bioengineered Protein Drugs Sales by Country (2027-2032) & (K Units)
Table 105. Europe Bioengineered Protein Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 106. Europe Bioengineered Protein Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 107. Asia Pacific Bioengineered Protein Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 108. Asia Pacific Bioengineered Protein Drugs Sales by Country (2021-2026) & (K Units)
Table 109. Asia Pacific Bioengineered Protein Drugs Sales by Country (2027-2032) & (K Units)
Table 110. Asia Pacific Bioengineered Protein Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 111. Asia Pacific Bioengineered Protein Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 112. South America Bioengineered Protein Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 113. South America Bioengineered Protein Drugs Sales by Country (2021-2026) & (K Units)
Table 114. South America Bioengineered Protein Drugs Sales by Country (2027-2032) & (K Units)
Table 115. South America Bioengineered Protein Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 116. South America Bioengineered Protein Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 117. Middle East and Africa Bioengineered Protein Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 118. Middle East and Africa Bioengineered Protein Drugs Sales by Country (2021-2026) & (K Units)
Table 119. Middle East and Africa Bioengineered Protein Drugs Sales by Country (2027-2032) & (K Units)
Table 120. Middle East and Africa Bioengineered Protein Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 121. Middle East and Africa Bioengineered Protein Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 122. Global Bioengineered Protein Drugs Sales by Type (2021-2026) & (K Units)
Table 123. Global Bioengineered Protein Drugs Sales by Type (2027-2032) & (K Units)
Table 124. Global Bioengineered Protein Drugs Sales Market Share by Type (2021-2026)
Table 125. Global Bioengineered Protein Drugs Sales Market Share by Type (2027-2032)
Table 126. Global Bioengineered Protein Drugs Revenue by Type (2021-2026) & (US$ Million)
Table 127. Global Bioengineered Protein Drugs Revenue by Type (2027-2032) & (US$ Million)
Table 128. Global Bioengineered Protein Drugs Revenue Market Share by Type (2021-2026)
Table 129. Global Bioengineered Protein Drugs Revenue Market Share by Type (2027-2032)
Table 130. Global Bioengineered Protein Drugs Price by Type (2021-2026) & (US$/Unit)
Table 131. Global Bioengineered Protein Drugs Price by Type (2027-2032) & (US$/Unit)
Table 132. Global Bioengineered Protein Drugs Sales by Application (2021-2026) & (K Units)
Table 133. Global Bioengineered Protein Drugs Sales by Application (2027-2032) & (K Units)
Table 134. Global Bioengineered Protein Drugs Sales Market Share by Application (2021-2026)
Table 135. Global Bioengineered Protein Drugs Sales Market Share by Application (2027-2032)
Table 136. Global Bioengineered Protein Drugs Revenue by Application (2021-2026) & (US$ Million)
Table 137. Global Bioengineered Protein Drugs Revenue by Application (2027-2032) & (US$ Million)
Table 138. Global Bioengineered Protein Drugs Revenue Market Share by Application (2021-2026)
Table 139. Global Bioengineered Protein Drugs Revenue Market Share by Application (2027-2032)
Table 140. Global Bioengineered Protein Drugs Price by Application (2021-2026) & (US$/Unit)
Table 141. Global Bioengineered Protein Drugs Price by Application (2027-2032) & (US$/Unit)
Table 142. Key Raw Materials
Table 143. Raw Materials Key Suppliers
Table 144. Bioengineered Protein Drugs Distributors List
Table 145. Bioengineered Protein Drugs Customers List
Table 146. Bioengineered Protein Drugs Industry Trends
Table 147. Bioengineered Protein Drugs Industry Drivers
Table 148. Bioengineered Protein Drugs Industry Restraints
Table 149. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Bioengineered Protein Drugs Product Image
Figure 5. Global Bioengineered Protein Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Bioengineered Protein Drugs Market Size (2021-2032) & (US$ Million)
Figure 7. Global Bioengineered Protein Drugs Sales (2021-2032) & (K Units)
Figure 8. Global Bioengineered Protein Drugs Average Price (US$/Unit) & (2021-2032)
Figure 9. Therapeutic Proteins Product Image
Figure 10. Vaccines Product Image
Figure 11. Monoclonal Antibodies Product Image
Figure 12. Autoimmune Disorder Product Image
Figure 13. Diabetes Product Image
Figure 14. Neurodegenerative Product Image
Figure 15. Infectious Disease Product Image
Figure 16. Cancer Product Image
Figure 17. Others Product Image
Figure 18. Global Bioengineered Protein Drugs Revenue Share by Manufacturers in 2025
Figure 19. Global Manufacturers of Bioengineered Protein Drugs, Manufacturing Sites & Headquarters
Figure 20. Global Top 5 and 10 Bioengineered Protein Drugs Players Market Share by Revenue in 2025
Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 22. Global Bioengineered Protein Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 23. Global Bioengineered Protein Drugs Sales by Region in 2025
Figure 24. Global Bioengineered Protein Drugs Revenue by Region in 2025
Figure 25. North America Bioengineered Protein Drugs Market Size by Country in 2025
Figure 26. North America Bioengineered Protein Drugs Sales Market Share by Country (2021-2032)
Figure 27. North America Bioengineered Protein Drugs Revenue Market Share by Country (2021-2032)
Figure 28. United States Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Canada Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. Europe Bioengineered Protein Drugs Market Size by Country in 2025
Figure 31. Europe Bioengineered Protein Drugs Sales Market Share by Country (2021-2032)
Figure 32. Europe Bioengineered Protein Drugs Revenue Market Share by Country (2021-2032)
Figure 33. Germany Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. France Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. U.K. Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Italy Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Netherlands Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Nordic Countries Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Asia Pacific Bioengineered Protein Drugs Market Size by Country in 2025
Figure 40. Asia Pacific Bioengineered Protein Drugs Sales Market Share by Country (2021-2032)
Figure 41. Asia Pacific Bioengineered Protein Drugs Revenue Market Share by Country (2021-2032)
Figure 42. China Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Japan Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. South Korea Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. India Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. Australia Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. China Taiwan Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. Southeast Asia Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Southeast Asia Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. South America Bioengineered Protein Drugs Market Size by Country in 2025
Figure 51. South America Bioengineered Protein Drugs Sales Market Share by Country (2021-2032)
Figure 52. South America Bioengineered Protein Drugs Revenue Market Share by Country (2021-2032)
Figure 53. Mexico Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. Brazil Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 55. Argentina Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 56. Colombia Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. Middle East and Africa Bioengineered Protein Drugs Market Size by Country in 2025
Figure 58. Middle East and Africa Bioengineered Protein Drugs Sales Market Share by Country (2021-2032)
Figure 59. Middle East and Africa Bioengineered Protein Drugs Revenue Market Share by Country (2021-2032)
Figure 60. Turkey Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 61. Saudi Arabia Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 62. UAE Bioengineered Protein Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 63. Global Bioengineered Protein Drugs Sales Market Share by Type (2021-2032)
Figure 64. Global Bioengineered Protein Drugs Revenue Market Share by Type (2021-2032)
Figure 65. Global Bioengineered Protein Drugs Price (US$/Unit) by Type (2021-2032)
Figure 66. Global Bioengineered Protein Drugs Sales Market Share by Application (2021-2032)
Figure 67. Global Bioengineered Protein Drugs Revenue Market Share by Application (2021-2032)
Figure 68. Global Bioengineered Protein Drugs Price (US$/Unit) by Application (2021-2032)
Figure 69. Bioengineered Protein Drugs Value Chain
Figure 70. Bioengineered Protein Drugs Production Mode & Process
Figure 71. Direct Comparison with Distribution Share
Figure 72. Distributors Profiles
Figure 73. Bioengineered Protein Drugs Industry Opportunities and Challenges
提及公司
Amoytop BiotechDr.Reddy’sFreseniusHualan BioPanacea BiotechProBioGenReliance Life SciencesShanghai United Cell BiotechnologyGlaxoSmithKlineEli LillyRocheMerckNovartisSanofi
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們